Danielle Brill
Stock Analyst at Truist Securities
(4.19)
# 585
Out of 5,182 analysts
106
Total ratings
48.42%
Success rate
16.79%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MAZE Maze Therapeutics | Maintains: Buy | $68 → $64 | $28.09 | +127.84% | 2 | Apr 14, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $515 → $505 | $309.66 | +63.08% | 4 | Apr 13, 2026 | |
| APGE Apogee Therapeutics | Initiates: Hold | $83 | $92.20 | -9.98% | 1 | Mar 18, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $17 | $9.16 | +85.59% | 1 | Mar 18, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $63 → $110 | $93.26 | +17.95% | 3 | Mar 9, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $114 → $83 | $71.77 | +15.65% | 8 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $86 → $95 | $76.75 | +23.78% | 4 | Feb 25, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $169 → $140 | $133.25 | +5.07% | 9 | Feb 17, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $38 | $39.66 | -4.19% | 3 | Jan 29, 2026 | |
| TECX Tectonic Therapeutic | Maintains: Buy | $64 → $60 | $29.51 | +103.32% | 3 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $16 → $22 | $29.30 | -24.91% | 6 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $45 | $29.99 | +50.05% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $190 | $130.01 | +46.14% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $9.99 | +370.47% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $441.20 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $21.28 | +12.78% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $17.58 | +195.79% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $20.57 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $54.64 | +44.58% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $9.49 | +89.67% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $21.55 | +596.06% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $177.35 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $849.04 | -28.74% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $22.17 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $59.70 | -16.25% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $35.14 | +45.13% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $11.67 | +756.90% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $72.43 | - | 9 | Sep 18, 2023 |
Maze Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $68 → $64
Current: $28.09
Upside: +127.84%
Alnylam Pharmaceuticals
Apr 13, 2026
Maintains: Buy
Price Target: $515 → $505
Current: $309.66
Upside: +63.08%
Apogee Therapeutics
Mar 18, 2026
Initiates: Hold
Price Target: $83
Current: $92.20
Upside: -9.98%
Climb Bio
Mar 18, 2026
Initiates: Buy
Price Target: $17
Current: $9.16
Upside: +85.59%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $63 → $110
Current: $93.26
Upside: +17.95%
Disc Medicine
Feb 27, 2026
Maintains: Buy
Price Target: $114 → $83
Current: $71.77
Upside: +15.65%
BridgeBio Pharma
Feb 25, 2026
Maintains: Buy
Price Target: $86 → $95
Current: $76.75
Upside: +23.78%
Neurocrine Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $169 → $140
Current: $133.25
Upside: +5.07%
Centessa Pharmaceuticals
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $38
Current: $39.66
Upside: -4.19%
Tectonic Therapeutic
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $29.51
Upside: +103.32%
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $29.30
Upside: -24.91%
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $45
Current: $29.99
Upside: +50.05%
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $130.01
Upside: +46.14%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $9.99
Upside: +370.47%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $441.20
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $21.28
Upside: +12.78%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $17.58
Upside: +195.79%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $20.57
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $54.64
Upside: +44.58%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $9.49
Upside: +89.67%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $21.55
Upside: +596.06%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $177.35
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $849.04
Upside: -28.74%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $22.17
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $59.70
Upside: -16.25%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $35.14
Upside: +45.13%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $11.67
Upside: +756.90%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $72.43
Upside: -